A novel agent effective against Clostridium difficile infection
Sofya Dvoskin, Wei-Chu Xu, Neal C Brown, Ivan B Yanachkov, Milka Yanachkova, George E Wright, Sofya Dvoskin, Wei-Chu Xu, Neal C Brown, Ivan B Yanachkov, Milka Yanachkova, George E Wright
Abstract
N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E) is a synthetic purine that selectively inhibits the replication-specific DNA polymerase of Clostridium difficile. MorE-DCBG and its analogs strongly inhibited the growth of a wide variety of C. difficile strains. When administered orally in a hamster model of C. difficile-specific colitis, 362E was as effective as oral vancomycin, the current agent of choice for treating severe forms of the human disease.
Figures
Source: PubMed